Humacyte (HUMA) Revenue (2020 - 2026)
Humacyte's (HUMA) quarterly Revenue came in at $406000.0 in Q2 2026, up 34.88% year-over-year from $301000.0 in Q2 2025, and down 17.98% quarter-over-quarter from $495000.0 in Q1 2026.
Powered by 
Analysis
Humacyte (HUMA) Revenue (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Revenue for 4 consecutive years, with $406000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Revenue rose 34.88% year-over-year to $406000.0 in Q2 2026; TTM through Jun 2026 was $2.1 million, a 159.29% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, changed N/A from the prior year.
- Revenue was $406000.0 for Q2 2026 at Humacyte, down from $495000.0 in the prior quarter.
- Over five years, Revenue peaked at $753000.0 in Q3 2025 and troughed at $301000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | 119.22 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 10.18 Mn |
| 3 | Iovance Biotherapeutics | 3.74 Bn | 3.44 Bn | 55.72 Mn | 99.31 Mn |
| 4 | Legend Biotech | 3.57 Bn | 2.61 Bn | 251.50 Mn | 387.50 Mn |
| 5 | uniQure | 3.00 Bn | 3.00 Bn | 5.49 Mn | 5.84 Mn |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | 490,000.00 |
| 7 | Precigen | 2.36 Bn | 2.36 Bn | 52.17 Mn | 54.98 Mn |
| 8 | Sarepta Therapeutics | 2.21 Bn | 1.42 Bn | 251.87 Mn | 401.25 Mn |
| 9 | Vericel | 1.95 Bn | 1.79 Bn | 56.40 Mn | 77.46 Mn |
| 10 | Humacyte | 132.90 Mn | 132.90 Mn | -825,000.00 | 406,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 406,000.00 |
| Mar 31, 2026 | 495,000.00 |
| Dec 31, 2025 | 467,000.00 |
| Sep 30, 2025 | 753,000.00 |
| Jun 30, 2025 | 301,000.00 |
| Mar 31, 2025 | 517,000.00 |
| Sep 30, 2021 | 241,000.00 |
| Sep 30, 2020 | 914,000.00 |